How to Acquire SPRAVATO™

SPRAVATO™ has a controlled distribution network that ensures SPRAVATO™ is distributed only to certified healthcare settings and certified pharmacies. SPRAVATO™ will not be delivered directly to patients

Learn more about acquiring SPRAVATO™ in your practice by selecting
one of the settings detailed below:

Healthcare Settings

Treatment center protocols should be followed for handling Schedule III products in accordance with federal, state, and local regulations and laws

  • Healthcare settings must be certified in the REMS in order to treat patients with SPRAVATO™
  • Healthcare professionals also must be properly licensed and hold an active DEA registration at site of care
  • REMS-certified healthcare settings can acquire SPRAVATO™ directly from full-line wholesalers or specialty distributors via standard buy-and-bill practice
  • Healthcare settings which are not REMS-certified will need to go through the certification process in order to order/dispense SPRAVATO™

Click here to find out more about REMS certification requirements
or call 1-855-382-6022

Buy-and-Bill Pathway

  • Healthcare Setting buys bulk drug supply from specialty distributor
  • Healthcare Setting stores and handles product in accordance with State and Federal regulations
  • Healthcare Setting treats patient with drug
  • Healthcare Setting bills payer
  • Healthcare Setting bills patients for cost share post payer payment

In the buy-and-bill process, a healthcare provider purchases a drug from a pharmaceutical wholesaler or specialty distributor. After administering the drug, the provider submits a claim for reimbursement for the drug and any other medical services.

Step 1: Initiate a benefits investigation

Step 2: Identify whether a prior authorization is required

Step 3: Identify the patient' s co-pay

Step 4: Write prescription/order medication

Step 5: Submit a claim

Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on SPRAVATO™.

Click here to learn more about Janssen CarePath support that may be available.




Indication for large populates

Important Safety Information